N/A N=40 Zilver PTX Delivery System
Peripheral Vascular Disease
Primary: Mean Percent Change in Stent Length Upon Deployment — -1.0 percentage of change in stent length — p=<0.01
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=20 Safety and Tolerability of MK-5478 in Participants With Hypertension (5478-001)
Hypertension
Primary: Number of Participants With One or More Adverse Events (AEs) — 5; 3; 3; 4 Participants
Phase 4 N=955 Prospective Trial of Tranexamic Acid in Cardiac Surgery
C.Surgical Procedure; Cardiac
Primary: Postoperative Blood Loss — 520; 490; 450 ml
Phase 4 N=131 Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents
Immune Response to Influenza Vaccine · Influenza A Virus Infection · Influenza B Virus Infection
Primary: Hemagglutination Inhibition (HI) Titer Response to Vaccine and Circulating Strains of Influenza — 99; 295; 96; 100 Titers
Phase 4 N=606 Study on Efficacy and Safety of Chondroitin Sulfate + Glucosamine Hydrochloride Versus Celecoxib in Knee Osteoarthritis
Knee Osteoarthritis
Primary: WOMAC Pain Subscale — 185.79; 184.67 units on a scale
Phase 4 N=79 Meropenem Dosage Strategy Based on PPK Model
Lower Respiratory Tract Infection
Primary: Clinical Success Rate — 28; 35 participants
Phase 1 N=5 Distribution of Neutrophils in Bronchial Mucosal Tissue in Asthma Patients Before and After 4 Weeks Treatment With AZD 5069
Asthma
Primary: Summary for Change From Baseline of Mean Global Semi-quantitative Score Values for Neutrophils in Bronchial Biopsies — -1.21 Units on a scale
Phase 2 N=112 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Dose Limiting Toxicities of EMD + RT and TMZ — 0; 0; 0 participants
Phase 2 N=13 CC-4047 (Pomalidomide) for Graft vs. Host Disease
Graft vs Host Disease
Primary: Overall Response (Complete Response + Partial Response + Other) — 7; 2; 0; 0 participants
Phase 3 N=496 A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Mean St.George's Respiratory Questionnaire (SGRQ) Total Score at Day 84 — -2.12; -6.15 Score on scale — p=<0.001
N/A N=501 Study Intended to Evaluate the Safety and Effectiveness of a Johnson & Johnson Vision Care Inc, (JJVCI) Contact Lens for Use on an Extended-wear Basis for up to 7 Days (6 Nights).
Myopia
Primary: Monocular Contact Lens Snellen Visual Acuity Worse Than 20/40 — 0; 0; 0; 0 Percentage of Subjects Eyes
N/A N=260 Prospective Observational Study on the Management of Patients With Relapsed or Refractory Follicular Lymphoma (OLYMPE)
Follicular Lymphoma
Primary: Percentage of Participants With Modalities of the Therapeutic Decision Before First Study Induction Treatment Phase — 81.9; 8.4; 6.3; 3.4 percentage of participants
Phase 2 N=31 Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
Adult Medulloblastoma
Primary: Objective Response (CR+PR) Sustained for ≥ 8 Weeks — 0; 0.15; 0 proportion of participants
Phase 3 N=150 Lurasidone Pediatric Autism Study
Autism
Primary: Change in Aberrant Behavior Checklist (ABC) Irritability Subscale Score at Week 6 — 8.8; 9.4; 7.5 units on a scale — p=0.5463
Phase 2 N=282 Mucin Balls and Corneal Inflammation Events
Corneal Inflammation · Corneal Infiltrative Events
Primary: Corneal Infiltrate Events - Phase I — 18.6; 5.7 percentage of subjects